1 Samadder NJ,Vierkant RA,Tillmans LS,et al.Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women[J].Gastroenterology,2013,145(2):348-556. 2 Gatalica Z,Vranic S,Xiu J,et al.High microsatellite instability(MSI-H)colorectal carcinoma:a brief review of predictive biomarkers in the era of personalized medicine[J].Fam Cancer,2016,15(3):405-412. 3 Lochhead P,Kuchiba A,Imamura Y,et al.Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication[J].J Natl Cancer Inst,2013,105(15):1151. 4 Kim JH,Kang GH.Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer[J].World J Gastroenterol,2014,20(15):4230-4243. 5 Chen CH,Jiang SS,Hsieh LL,et al.DNA methylation identifies loci distinguishing hereditary nonpolyposis colorectal cancer without germ line MLH1/MSH2 mutation from sporadic colorectal cancer[J].Clin Transl Gastroenterol,2016,7(12):208. 6 Peltomki P.Update on Lynch syndrome genomics[J].Fam Cancer,2016,15(3):385-393. 7 Ward RL,Dobbins T,Lindor NM,et al.Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the colon cancer family registry[J].Genet Med,2013,15(1):25-35. 8 Xiao Y,Freeman GJ.The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy[J].Cancer Discov,2015,5(1):16-18. 9 Lynch HT,Snyder CL,Shaw TG,et al.Milestones of Lynch syndrome:1895-2015[J].Nat Rev Cancer,2015,15(3):181-194. 10 Tariq K,Ghias K.Colorectal cancer carcinogenesis:a review of mechanisms[J].Cancer Biol Med,2016,13(1):120. 11 Hitchins MP,Wong JJL,Suthers G,et al.Inheritance of a cancer-associated MLH1 germ line epimutation[J].N Engl J Med,2007,356(7):697-705. 12 Ligtenberg MJL,Kuiper RP,Chan TL,et al.Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1[J].Nat Genet,2009,41(1):112-117. 13 Zhang J,Lindroos A,Ollila S,et al.Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers[J].Cancer Res,2006,66(2):659-664. 14 Drescher KM,Sharma P,Lynch HT.Current hypotheses on how microsatellite instability leads to enhanced survival of lynch syndrome patients[J].Clin Dev Immunol,2010,2010(1):170432. 15 Zoratto F,Rossi L,Verrico M,et al.Focus on genetic and epigenetic events of colorectal cancer pathogenesis:implications for molecular diagnosis[J].Tumour Biol,2014,35(7):6195-6206. 16 Hugen N,Verhoeven RHA,Radema SA,et al.Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma[J].Ann Oncol,2013,24(11):2819-2824. 17 Scarpa M,Ruffolo C,Canal F,et al.Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance[J].Oncotarget,2015,6(41):43472-43482. 18 Zong L,Abe M,Ji J,et al.Tracking the correlation between CpG island methylator phenotype and other molecular features and clinicopathological features in human colorectal cancers:a systematic review and meta-analysis[J].Clin Transl Gastroenterol,2016,7(3):151. 19 Tanaka H,Deng G,Matsuzaki K,et al.BRAF mutation,CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non‐mucinous colorectal cancer[J].Int J Cancer,2006,118(11):2765-2771. 20 Yoon YS,Kim J,Hong SM,et al.Clinical implications of mucinous components correlated with microsatellite instability in patients with colorectal cancer.[J].Colorectal Dis,2015,17(8):161-167. 21 Akiyama S,Kikuchi D,Mitani T,et al.A case of mucinous adenocarcinoma in the setting of chronic colitis associated with intestinal spirochetosis and intestinal stricture[J].Medicine,2015,94(4):e493. 22 Dudley JC,Lin MT,Le DT,et al.Microsatellite instability as a biomarker for PD-1 blockade[J].Clin Cancer Res,2016,22(4):813-820. 23 Bae JM,Kim JH,Kang GH.Epigenetic alterations in colorectal cancer:the CpG island methylator phenotype[J].Histol Histopathol,2013,28(5):585-595. 24 Llosa NJ,Cruise M,Tam A,et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J].Cancer Discov,2015,5(1):43-51. 25 Gandini S,Massi D,Mandalà M.PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies:A systematic review and meta-analysis[J].Crit Rev Oncol Hematol,2016,100:88-98. 26 Schwitalle Y,Kloor M,Eiermann S,et al.Immune response against frame shift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers[J].Gastroenterology,2008,134(4):988-997. 27 Yuan L,Chi Y,Chen W,et al.Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency[J].Int J Clin Exp Med,2015,8(11):20988-21000. 28 Lynch HT,DrescherK,Knezetic J,et al.Genetics,biomarkers,hereditary cancer syndrome diagnosis,heterogeneity and treatment:a review[J].Curr Treat Options Oncol,2014,15(3):429-442. 29 Herman JG,Umar A,Polyak K,et al.Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma[J].Proc Natl Acad Sci U S A,1998,95(12):6870-6875. 30 Kim JH,Bae JM,Cho NY,et al.Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype:implications in the serrated neoplasia pathway[J].Oncotarget,2016,7(12):14095-14111. 31 Ward RL,Cheong K,Ku SL,et al.Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability[J].J Clin Oncol,2003,21(20):3729-3736. 32 Rhee YY,Kim MJ,Bae JM,et al.Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level[J].Ann Surg Oncol,2012,19(11):3441-3448. 33 Rosty C,Williamson EJ,Clendenning M,et al.Re:Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication[J].J Natl Cancer Inst,2014,106(8):1151-1156. 34 Cohen R,Svrcek M,Dreyer C,et al.New therapeutic opportunities based on DNA mismatch repair and BRAF status in metastatic colorectal cancer[J].Curr Oncol Rep,2016,18(3):1-10. 35 Venderbosch S,Nagtegaal ID,Maughan TS,et al.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients:a pooled analysis of the CAIRO,CAIRO2,COIN,and FOCUS studies[J].Clin Cancer Res,2014,20(20):5322-5330. 36 Dienstmann R,Guinney J,Delorenzi M,et al.Colorectal cancer subtyping consortium(CRCSC)identification of a consensus of molecular subtypes[J].Gondwana Res,2014,25(4):1484-1500. 37 Taieb J,Le Malicot K,Penault-Llorca FM,et al.Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable(MSS),stage III colon cancers(CC)from patients(pts)treated with adjuvant FOLFOX+/-cetuximab:A pooled analysis of 3934 pts from the PETACC8 and N0147 trials[J].J Clin Oncol,2015,33(15):3507. |